HAIC + durvalumab + tremelimumab + bevacizumab

This is a combination therapy consisting of hepatic arterial infusion chemotherapy (HAIC), durvalumab, tremelimumab, and bevacizumab. - **HAIC** is a locoregional chemotherapy technique where chemotherapeutic agents are delivered directly into the hepatic artery to target liver tumors, commonly used in hepatocellular carcinoma (HCC). - **Durvalumab** is a human monoclonal antibody that targets programmed death-ligand 1 (PD-L1), blocking its interaction with PD-1 and CD80 to enhance anti-tumor immune responses. - **Tremelimumab** is a human monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), promoting T-cell activation and priming the immune response against cancer cells[4][6][7]. - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby suppressing angiogenesis required for tumor growth. This multi-modal regimen aims to combine direct cytotoxic effects on liver tumors via HAIC with systemic immunotherapy and antiangiogenic therapy for synergistic efficacy in advanced or unresectable HCC.

Brand names

ImfinziImjudoAvastin

Other names

HAIC + Durvalumab + Tremelimumab + BevacizumabHAIC + Durvalumab + Tremelimumab + Bevacizumab in Unresectable HCC